Link copied to your clipboard
Leafly Leafly ® Loading…
advertise on Leafly
Take me to...
  • Weed dealsShop strains and products near you
  • Dispensaries mapFind stores nearby
  • Strains, strains, strainsLeafly's world-class database
  • Leafly Strain of the YearThe 2021 crown goes to…
  • Cannabis 101Guides, how-tos, history
  • Grow guideA hub for home growers
  • Strains for pain reliefPlus other feelings & effects
item added to bag
add to bag image
view bag
Delivery
new
DispensariesDealsStrainsProductsCBDDoctorsCannabis 101Social impact

Get local results

 Current general location:  
Enter your location to see results closest to you.
-or-
We do not share your location with anyone.

Browse Leafly

  • Your Account
  • Join Leafly
  • Advertise on Leafly
  • Home
  • Delivery
    new
  • Strains
  • Dispensaries
  • CBD
  • Products
  • Deals
  • News
  • Learn
  • Cannabis 101
  • Social impact
  • Doctors
  • Lab partners
    • Leafly.comUSA flag
    • Leafly.caCanadian flag
    • Leafly.deGerman flag
  • Help
  • Sign out
Welcome to Leafly.
Thanks for stopping by.

Are you at least 21?

Darn! You're not old enough to use Leafly.

Redirecting you to

By accessing this site, you accept the Terms of Use and Privacy Policy.

We use cookies for certain features and to improve your experience. See our Cookie Policy and Privacy Policy to learn more.

    • News
    • Cannabis 101
    • Growing
    • Strains & products
    • CBD
    • Politics
    • Health
    • Lifestyle
    • Science & tech
    • Industry
    • Reports
    • Canada
    • Podcasts
    • Leafly TV
    • Leafly Lists
Politics

FAQ: What We Know About Jeff Sessions’ DOJ Action Against Legal Cannabis

Ben AdlinPublished on January 4, 2018 • Last updated July 28, 2020
Image Test
Sen. Jeff Sessions, R-Ala., center, talks with reporters after a meeting with Republican presidential candidate Donald Trump and the Senate Republican Conference, Thursday, July 7, 2016, at the National Republican Senatorial Committee headquarters in Washington. (AP Photo/Alex Brandon)

US Attorney General Jeff Sessions announced Thursday that he is rescinding the Cole memo, an Obama-era Department of Justice guideline that set a policy of federal noninterference with state-legal cannabis. While the move itself doesn’t trigger any immediate legal action, it’s a sign that the federal prosecutors may intend to ramp up legal actions against cannabis businesses in legal states.

We’ve tried to answer a few of the most common questions about what Sessions’ move might mean. Do you have others? Let us know in the comments. We’ll be updating this page as the situation develops.

Does This Mean the End of Legal Cannabis?

No. Take a deep breath. The sky is not falling. Sessions’ action today rescinds a Department of Justice policy guideline, not a law. Essentially, the move tells federal prosecutors across the country that DOJ no longer officially opposes them interfering with legal cannabis.

“I think this is an attempt to suppress the growth of the industry, not to kill us.”

Worrisome? Absolutely. The end of legalization? Let’s not get ahead of ourselves.

In Oakland, Harborside co-founder Steve DeAngelo, who in 2016 successfully fended off a yearslong federal enforcement action, said he sees Sessions’ move as a way to slow what’s been a rapid rollout of legal cannabis. “I don’t think this is a big deal,” he told Leafly. “I think this is an attempt to suppress the growth of the industry, not to kill us. It is more of a delaying tactic than a knife to our throat.”

What Happens Next?

Most likely, nothing will happen immediately. While undoing the Cole memo opens the door to federal interference with state-legal cannabis programs, Sessions’ move itself doesn’t trigger any legal action.

If there is any sort of crackdown, the first actions would likely come from individual US attorneys, who oversee federal prosecutions in their respective jurisdictions. Their offices could file civil or criminal actions against state-legal cannabis businesses (or their landlords) in an effort to shutter the businesses.

Why Is Sessions Doing This?

It’s no secret that the attorney general is opposed to cannabis. He’s derided its use in medical treatment and said that “good people don’t smoke marijuana.” He’s claimed that cannabis could make the national opioid epidemic worse despite evidence that opioid use actually decreases in legal states. But for the past year or so, Sessions has been more talk than action.

Part of the motivation behind his decision to rescind the Cole memo on Thursday could be to chill cannabis activity in state-legal markets. Sessions has formally criticized programs in adult-use states, yet legalization keeps stubbornly spreading, fueled by broad public support from liberals and conservatives alike. Las Vegas launched legal adult-use sales in July, and California opened adult-use retail stores to significant fanfare on New Year’s Day. Sessions may be trying to steal those states’ thunder.

Are There Other Federal Protections?

For now, yes, but not many. The Rohrabacher–Blumenaur amendment, a provision included in a federal spending bill, currently prevents the Justice Department from spending resources to prosecute state-legal medical marijuana. But the measure doesn’t offer any cover for adult-use cannabis, and it’s only in place until later this month; Congress will need to renew that protection for it to continue. It’s possible, however, that Sessions’ reversal of the Cole memo could actually encourage congressional representatives to take further action to safeguard state-legal cannabis.

What Can Be Done?

After last year, you’re tired of hearing this, but: Call your representatives in Congress! Tell them to support measures that protect states’ rights to regulate cannabis as they see fit. Encourage them to support renewing the Rohrabacher–Blumenauer amendment—and while you’re at it, tell them to expand its protections to adult-use cannabis. While federal legalization remains a controversial issue for many politicians to get behind, there’s significant public support for leaving regulation to the states.

Contact information for members of the Senate and House of Representatives is available online.

Do State Officials Have to Hand Over Licensing Records?

Good question. Names of state-licensed cannabis companies, locations, and principal owners are already matters of public record. See: California’s Cannabis Control Bureau website. Any federal DEA agent can see the information just as easily as you or I can.

Leafly’s Peter Hecht put the question to San Francisco cannabis attorney Matt Kumin. Kumin said the Justice Department can indeed take advantage of public information on cannabis businesses, including licensing information, and can be expected to subpoena state tax and sales records on individual cannabis businesses, which are not public. 

“They may try that,” Kumin said. “You will likely see something like that end up in a court battle—because I don’t think California will cooperate with a subpoena. This is the United States of California vs. the United States of America…I think California is well down the road in opposition to federal policies here.”

Does This Affect Banking?

No, not directly. The US Treasury Department’s 2014 policy guidance on banks and credit unions that do business with cannabis-related companies remains unaffected by today’s Justice Department move, as far as we can tell. That guidance can be found here.

Leafly’s Cannabist Capitalist columnist, Alan Brochstein, reminded us this afternoon that the Financial Crimes Enforcement Network (FinCEN), which issued the guidance to banks, is part of the Treasury Department, not the Justice Department. Jeff Sessions has no say in Treasury policy.

Although the FinCEN guidelines remain in place, today’s move by the Justice Department will undoubtedly cause some financial institutions to take a hard look at their current politics and relationships with cannabis-related companies.

As of July 2017, FinCEN reported that 296 banks and 94 credit unions were providing banking services to marijuana-related businesses:

 

cole memoJeff Sessionslaw enforcementlaws
Ben Adlin's Bio Image
Ben Adlin

Ben Adlin is a Seattle-based writer and editor who specializes in cannabis politics and law. He was a news editor for Leafly from 2015-2019. Follow him on Twitter: @badlin

View Ben Adlin's articles

The latest in Politics

Show all
Weed buyer beware: THC inflation is getting out of hand image
Science & tech
Weed buyer beware: THC inflation is getting out of hand
Nick Jikomes, PhD
28 grams of game: GUMBO's Luka Brazi image
Industry
28 grams of game: GUMBO's Luka Brazi
Mikhail Harrison
New York approves first conditional processor licenses and policy director image
Industry
New York approves first conditional processor licenses and policy director
Amelia Williams
Leafly's dictionary of weed slang image
Cannabis 101
Leafly's dictionary of weed slang
Janessa Bailey and Pat Goggins
Get good reads, local deals, and strain spotlights delivered right to your inbox.
Thank you for subscribing!
We won’t share this without your permission

By submitting this form, you will be subscribed to news and promotional emails from Leafly and you agree to Leafly's Terms of Service and Privacy Policy. You can unsubscribe from Leafly email messages anytime.



Hotbox your inbox

Get good reads, local deals, and strain spotlights delivered right to your inbox.

Something went wrong, please try again.

By providing us with your email address, you agree to Leafly’s Terms of Service and Privacy Policy. Offer valid for new Leafly subscribers. Available to US residents only, valid only where legal.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play

  • List your store
  • List your CBD store
  • List your brand
  • List your practice
  • Certify your lab
  • Business log in

  • About us
  • Careers
  • Newsroom
  • Investor relations
  • Contact us
  • FAQs
  • Accessibility

  • Los Angeles
  • Seattle
  • Portland
  • San Francisco
  • Toronto
  • Detroit

  • Terms of use
  • Commercial terms of use
  • Privacy policy
  • Do not sell my personal information

* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2022 Leafly Holdings, Inc.
Leafly and the Leafly logo are registered trademarks of Leafly Holdings, Inc. All Rights Reserved.